Insider Selling: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Sells 3,356 Shares of Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Diana Hausman sold 3,356 shares of the business’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the completion of the transaction, the insider now directly owns 373,876 shares of the company’s stock, valued at approximately $4,718,315.12. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Zentalis Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ:ZNTL traded up $0.09 on Thursday, reaching $12.52. The company had a trading volume of 592,438 shares, compared to its average volume of 781,793. The firm has a market capitalization of $889.05 million, a PE ratio of -2.74 and a beta of 1.82. Zentalis Pharmaceuticals, Inc. has a 52-week low of $9.56 and a 52-week high of $31.46. The firm’s 50 day simple moving average is $13.70 and its 200-day simple moving average is $13.43.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.77) by $0.91. The firm had revenue of $40.56 million for the quarter, compared to analysts’ expectations of $35.00 million. During the same period in the previous year, the company posted ($1.07) earnings per share. As a group, equities research analysts predict that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ZNTL shares. HC Wainwright lowered their price target on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday. Stifel Nicolaus dropped their target price on shares of Zentalis Pharmaceuticals from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Wedbush increased their price target on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Zentalis Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $37.14.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ZNTL. Eventide Asset Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 47.9% during the fourth quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after buying an additional 3,745,936 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Zentalis Pharmaceuticals by 6.2% in the third quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock worth $105,047,000 after buying an additional 307,490 shares during the last quarter. Federated Hermes Inc. grew its holdings in Zentalis Pharmaceuticals by 10.9% during the fourth quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock worth $32,733,000 after acquiring an additional 212,872 shares during the period. Decheng Capital LLC acquired a new position in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $31,809,000. Finally, Wellington Management Group LLP increased its holdings in shares of Zentalis Pharmaceuticals by 0.5% during the 3rd quarter. Wellington Management Group LLP now owns 1,917,105 shares of the company’s stock valued at $38,457,000 after purchasing an additional 8,661 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.